.jpeg "Gleneagles Hospital Launches Renal Denervation Centre in Mumbai")
Gleneagles Hospital, Mumbai, partners with Medtronic India to launch a Renal Denervation Therapy Centre, offering advanced treatment for resistant hypertension and improving outcomes.
.jpeg "Indoco Remedies Gets US FDA Approval for Brivaracetam Oral Solution")
Indoco Remedies gets US FDA approval for its generic brivaracetam oral solution, 10 mg/mL, treating partial-onset seizures. Manufactured in Goa, it's a milestone for the company.
Eris Lifesciences has partnered with Natco Pharma to commercialize semaglutide in India, ahead of the patent expiry of the blockbuster diabetes and weight-loss drug ingredient. The launch is expected in March 2026.
Bayer's Nubeqa receives expanded approval in India for metastatic hormone-sensitive prostate cancer, offering a non-chemotherapy treatment with ADT for advanced cases.
Akums Drugs & Pharmaceuticals Ltd. has secured EU GMP certification for two India plants and entered the UK market with MHRA approval for Rivaroxaban, strengthening its push into regulated European markets.
Lupin has secured European Commission approval for its biosimilar ranibizumab, marking a major step in expanding access to advanced eye care treatments across the European Union.
Dr. Reddy’s Laboratories Ltd. has secured USFDA review for its proposed interchangeable abatacept biosimilar, DRL_AB, positioning itself as the first to file a BLA in this segment and strengthening its biologics footprint in the US market.
BahiaFarma has joined hands with Biocon Biologics and Bionovis to develop and manufacture Pertuzumab for HER2-positive breast cancer, strengthening Brazil’s public healthcare supply and deepening India-Brazil pharma collaboration.
Morepen Laboratories has secured a Rs 825 crore multi-year CDMO contract from a global pharmaceutical company, marking one of its largest mandates and reinforcing its growing presence in global manufacturing partnerships.
Lilly and Company has announced that its Retevmo (selpercatinib) has met its primary endpoint in the LIBRETTO-432 Phase 3 trial, showing a significant improvement in event-free survival for early-stage RET fusion-positive NSCLC patients.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")